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Aging, defined as “increasing mortality with increas-
ing chronological age in populations in the wild” [1], also
known as “actuarial senescence in the wild” [2], or “pro-
gressive loss of function accompanied by decreasing fer-
tility and increasing mortality with advancing age” [3], is
observed in the wild for many species [1, 4-6], our species
included [7].
The theories that try to explain aging are many [8-
10] and, in general, belong to one of only two very differ-
ent general interpretations [11, 12], which for their
important and opposite implications deserve the defini-
tion of paradigms in the meaning proposed by Kuhn [13].
The first, or “old”, paradigm includes various
hypotheses that justify aging as due to inevitable damag-
ing factors that are insufficiently contrasted by natural
selection for various reasons. The second, or “new”, par-
adigm includes theories that explain aging as a specific
function, or program, which is favored by natural selec-
tion, at the supra-individual level, under particular con-
ditions [10, 12]. The new paradigm interprets aging as a
particular type of phenoptosis [14] (“programmed death
of an individual” [15]), a concept that includes many dif-
ferent phenomena, known for a long time [4], but not
considered in their entirety and for their important impli-
cations until recent times [16].
In this work, the evidence in support of the new par-
adigm and against the old paradigm [10, 11] and a less
concise description of aging physiology [17] is not
expounded for brevity. This work tries to propose feasible
interventions in the aging process that are consequent to
the main concept of the new paradigm: indeed, if aging is
a function, i.e. a physiological program that is genetically
determined and regulated, and if aging mechanisms are
sufficiently known, it should be possible to conceive pos-
sible modifications of this program that could hamper or
even cancel age-related fitness decline. In contrast, this is
not at all likely if, as proposed by the old paradigm, aging
is an inevitable consequence of the cumulative effect of
various damaging factors that act on many cellular and
organismal processes [18].
Within the new paradigm, the theory that explains
aging as a consequence of telomere shortening and the
consequent: (i) progressive inhibition of cell functions
and (ii) cell senescence (Fossel’s “cell senescence gener-
al model of aging” [17, 19, 20]) will be defined as “telom-
ere theory” of aging and described in brief in the next sec-
tion. Afterwards, some possible effective methods to
modify aging will be proposed.
PREMISES
Technical reservations. The methods that subse-
quently will be expounded require in various steps the
modifications of DNA segments by appropriate means.
Currently, the technique that seems most feasible regard-
ing both cost and feasibility, in comparison with other
means such as ZFNs (zinc finger nucleases) and TALENs
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(transcriptional activator-like effector nucleases), is the
so-called CRISPR-CAS9 (clustered regularly inter-
spaced short palindromic repeat–CRISPR-associated
nuclease 9) technique [21, 22].
Regarding this technique or about any other possible
means, in particular for the possible necessity of inserting
longer DNA segments, a critical element is the accuracy
and reliability of DNA modifications associated with this
method [23, 24]. Moreover, recent works have shown
ways to greatly ameliorate the precision of the CRISPR-
CAS9 technique [25, 26].
This criticality varies in a fundamental way accord-
ing to the type of experiment:
– Level 1: For example, if we operate on yeast cells
or on cultured cells or on animals, possible errors in DNA
changes reduce the certainty and the accuracy of the
results but do not involve consequences of pathological
relevance;
– Level 2: If we act on human individuals no longer
in the reproductive stage and suffering from diseases for
which a cure is desperately sought, the imprecision of the
changes could reduce the effectiveness of the results or
even confer negative effects on the health of the affected
subject as a result of unexpected DNA alterations, but will
have no effect on genetic heritage;
– Level 3: In contrast, by operating on human sub-
jects who may reproduce, the desired genetic modifica-
tions in germ line cells (in addition to the ethical reserva-
tions of the next point) could be accompanied by unex-
pected and undesired changes in other segments of DNA
molecules that will be transmitted to subsequent genera-
tions.
These considerations imply that the degree of relia-
bility of the possible techniques to modify DNA (i) is not
critical for experiments of level 1; (ii) is critical and pre-
liminary for experiments or treatments of level 2; (iii) is
extremely critical and strongly preliminary for experi-
ments or actions of level 3.
The observations outlined here, in very general
terms, should always be considered for the possible
actions discussed in this work. They will not be repeated
but shall be considered as always implied in any proposal
that will be formulated.
Ethical reservations. Any test or treatment or action
on humans, or on living beings in general, requires an
ethical evaluation; all the more for work on genetic infor-
mation that will be transmitted to subsequent genera-
tions. For the proposals set out in this work, we need two
kinds of ethical evaluations, quite different from each
other.
The first type relates to the possible dangers to the
health of those affected by the experiments or by the pro-
posed actions. In general, for this type of hazard, it is
essential first of all to conduct a series of experiments at
the level of cultured cells and/or on other species. Only at
a later stage will experiments on individuals suffering
from serious and incurable diseases and not a condition to
reproduce be admissible.
The second type of ethical evaluations is radically
different. According to the prevailing conception, i.e. the
old paradigm, aging results from the cumulative effect of
various degenerative processes and so the care of one or
more (or even all) aspects of aging is only the cure for var-
ious diseases. According to this paradigm, there is no eth-
ical problem in procedures that contrast the aging
process. Conversely, if the aging process is conceived of as
a genetically determined and regulated phenomenon, an
idea that is implicit to a detailed description of the mech-
anisms that carry it into effect and is a prerequisite for the
proposals that afterwards will be here formulated, it is no
longer possible to conceive aging as a sum of diseases or,
on the whole, as a complex disease. By defining a disease
as an alteration of a normal physiological process, it fol-
lows that aging may be “modified” but not “cured”
because aging is a normal physiological process and not a
disease. It would be different if aging, although normal,
was equated to a medical condition due to its discomforts
and impairments, but this different definition of disease
should also be carefully evaluated in ethical terms.
Therefore, actions that modify aging require a partic-
ular ethical evaluation. Even more, possible actions that
change the rates and manifestations of the aging process
by gene modifications that will be transmitted to subse-
quent generations, as they are changes to human nature,
need a very particular ethical evaluation that is beyond the
scientific limits and falls within the ethical, religious,
philosophical, and political fields. Consequently, the pos-
sibility of modifying aging, regardless of technical feasibil-
ity and of possible dangers associated with the procedures,
needs assessments and decisions that are beyond mere sci-
entific competence.
MECHANISMS OF AGING
ACCORDING TO THE TELOMERE THEORY
Aging mechanisms in Saccharomyces cerevisiae.
Saccharomyces cerevisiae (yeast), a unicellular species,
shows some phenomena that may be somehow considered
as aging, if it is precisely defined, as aforesaid, “increas-
ing mortality with increasing chronological age in popu-
lations in the wild” [1].
In fact, each yeast cell reproduces by division into
two cells, “mother” and “daughter” cells, which are not
perfectly equal. The daughter cell is identical to the par-
ent cell, while the cells of the mother lineage can repro-
duce only a limited number of times (in 3 days, for about
25-35 duplications [27]). In proportion to the number of
duplications, two phenomena are observed: (i) increasing
metabolic alterations [28-32]; (ii) growing vulnerability
to replicative senescence and apoptosis [28, 29, 31, 32].
These phenomena are a likely explanation of why some
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individuals die and others survive under particular condi-
tions of stress. However, in the mother lineage, the death
rate increases with an exponential dynamic as a function
of the number of duplications [33]. This is similar to the
age-related increase in mortality shown by many multi-
cellular species [5, 6] and may be considered within the
concept of aging, as underlined before.
In yeast, DNA is linear, as for all eukaryotic cells,
and not circular as for prokaryotes. In each replication,
the enzyme DNA polymerase does not duplicate a small
terminal part of the DNA molecule (the telomere) [34,
35]. The necessity of an enzyme able to restore telomere
integrity was predicted in 1973 [36] and some years later
the existence of this enzyme (telomerase) was demon-
strated [37].
In yeast, telomerase is always perfectly active both in
mother and daughter cells and there is no reduction in
telomere length with each duplication [38-40].
In mother cells, the metabolic alterations and the
vulnerability to replicative senescence and apoptosis,
which increases after each duplication, are caused by a
particular mechanism that is not related to telomere
shortening, as in multicellular eukaryotes (see below). In
yeast mother cells, proportionally to the number of repli-
cations, there is the accumulation of particular mole-
cules, defined as extrachromosomal ribosomal DNA cir-
cles (ERCs) [41]; “several lines of evidence suggest that
accumulation of ERCs is one determinant of life span”
[30].
Specifically, a particular type of yeast mutant indi-
rectly shows that the accumulation of ERCs interferes
with the action of that part of the DNA molecule adjacent
to the telomere, the subtelomere, and that in these
mutants, interference is analogous to what happens in
eukaryotic multicellular organisms, where subtelomere
repression is a consequence of telomere shortening due to
telomerase inactivity. In fact, tlc1∆ mutants, whose
telomerase is inactive, show telomere shortening both in
mother and daughter cells. However, the cells of the
daughter cell lineage, although they show no ERC accu-
mulation like normal strains, manifest all the alterations
of mother lineage cells with an equal number of duplica-
tions. In particular, the overall expression of genes,
defined as the transcriptome, is similar [30].
Experiments in yeast have allowed us to hypothesize
that: “One model of telomere-gene expression linkage is
an altered chromosomal structure (Ferguson et al., 1991),
such as a heterochromatin “hood” that covers the telom-
ere and a variable length of the subtelomeric chromosome
(Fossel, 1996; Villeponteau, 1997; Wright et al., 1999). As
the telomere shortens, the hood slides further down the
chromosome (the heterochromatin hood remains invari-
ant in size and simply moves with the shortening termi-
nus)… the result is an alteration of transcription from
portions of the chromosome immediately adjacent to the
telomeric complex, usually causing transcriptional silenc-
ing, although the control is doubtless more complex than
merely telomere effect through propinquity (Aparicio and
Gottschling, 1994; Singer et al., 1998; Stevenson and
Gottschling, 1999). These silenced genes may in turn
modulate other, more distant genes (or set of genes).
There is some direct evidence for such modulation in the
subtelomere…” [19].
The gradual repression of subtelomeric DNA,
caused by the accumulation of ERCs in normal yeast or
by telomere shortening and heterochromatin hood sliding
in yeast tlc1∆ mutants, has been known from some time
and defined as the “telomere position effect” [42]. It has
regulatory effects on gene expression in distant parts of
the DNA molecule [43]. Perhaps, due to its effects, it is
better to substitute the neutral expression “telomere posi-
tion effect” with “gradual cell senescence”, which has a
descriptive and interpretative value [10]. These concepts
are illustrated in Fig. 1.
Regarding the passage from a normal state to
replicative senescence and apoptosis, possible analogies
with the cell senescence program (replicative
senescence + on/off senescence) in multicellular eukary-
otes have been proposed (see below).
AGING MECHANISMS
IN MULTICELLULAR EUKARYOTES
“Gradual cell senescence”. In vertebrates, in cells
where telomerase is inactive or partially active, the telom-
ere shortens with each duplication and the sliding of the
heterochromatin hood progressively represses the sub-
telomere. In contrast, in cells where telomerase is per-
fectly active (e.g. germ line cells), the telomere does not
shorten and the subtelomere is not repressed [19]. The
first case is analogous to that of yeast tlc1∆ mutants,
daughter lineage cells, while the second case is analogous
to that of normal daughter lineage cells (Fig. 2).
Regarding the alterations to subtelomere regulatory
actions caused by the progressive sliding of the hete-
rochromatin hood, it is possible to hypothesize that the
subtelomere has a series of regulatory sequences (“r”),
which carry on their actions on distant parts of the DNA,
and, one after the other, are progressively covered and
repressed by the heterochromatin hood (Fig. 3).
The hypothesis of the existence of “r” sequences is
supported by the structure of the subtelomere, which has
an “unusual structure: patchworks of blocks that are
duplicated” [44]. Moreover, “a common feature associat-
ed with subtelomeric regions in different eukaryotes is the
presence of long arrays of tandemly repeated satellite
sequences” [45].
This “long arrays of tandemly repeated satellite
sequences”, an “unusual structure” that characterizes the
telomere and is apparently without meaning and useless,
therefore would be a general regulator of cell functions
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progressively inhibited by the knob of telomere shorten-
ing (or, in yeast, of ERC accumulation) and so this could
be the pivotal mechanism of aging.
According to this interpretation, the subtelomere
might be defined as that part of DNA that is contiguous to
the telomere and has general regulatory functions. One of
its ends is easily defined by the beginning of telomere
monotone sequence, while the other end is where repres-
sion is at the highest possible level before the obligatory
triggering of the cell senescence mechanism caused by
excessive telomere shortening.
“Replicative senescence”, “on/off senescence”, “cell
senescence program”. A simplistic hypothesis could be that
the cell becomes unable to duplicate (replicative senes-
Fig. 2. a, b) Analogy between normal yeast, daughter lineage, and germ line cells in vertebrates (or, in general, in multicellular eukaryotes);
c, d) analogy between yeast tlc1∆ mutants, daughter lineage, and vertebrate somatic cells.
a
b
c
d
Fig. 1. In yeast: a) normal stock, daughter lineage, the telomere is not shortened and the subtelomere is not repressed; b) normal stock, moth-
er lineage, after each duplication, the telomere is not shortened but the subtelomere is progressively repressed by ERC accumulation; c) tlc1∆
mutants, daughter lineage, after each duplication, the telomere is shortened and the subtelomere is repressed by sliding of the heterochro-
matin hood and not by ERC accumulation.
a
b
c
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cence) only when telomere shortening reaches a critical
value. However, the growth potential of a cell culture shows
not an abrupt collapse of duplication capacities, i.e. con-
temporary replicative senescence for all cells after a certain
number of duplications, but a progressive decrease related
to telomere length reduction [46, 47]. A brilliant explana-
tion for this phenomenon was proposed by Blackburn [48].
A protein hood (likely the same aforementioned het-
erochromatin hood [10]) caps the telomere, and there is a
continuous oscillation between two telomere states:
“uncapped” and “capped”. The first state, whose dura-
tion is related to telomere shortening, is vulnerable to the
passage to replicative senescence (“noncycling” stage),
while the other state is resistant to replicative senescence.
Even with activated telomerase and telomeres at the max-
imum length, with each division there is a short period of
uncapped state and a small percentage of cells shows
replicative senescence [48].
As the percentage of time in which the telomere is
uncapped and vulnerable is related to the progressive sub-
telomere repression, and as this repression is related to
the gradual reduction of the relative telomere length (see
before) and not to the initial length of the telomere (see
next section), it is proper to assume that the oscillation
between capped and uncapped states is somehow regulat-
ed by subtelomeric repetitive sequences, which might be
the same before defined as “r”. In Fig. 4, these sequences
are indicated with the letter “r”.
Stem cells, which, unlike germ line cells, show
telomerase activity that only partially preserves telomere
length [49], are therefore limited in their replacement
capacities of the elements eliminated by cell turnover [19].
The cellular phenomenon described by Blackburn as
the shift to a “noncycling state”, i.e. replicative senes-
cence, in fact is part of so-called “cell senescence”, well-
defined as a “fundamental cellular program” [50]. It is
characterized both by replicative senescence and by the
altered expression of many genes in a way that jeopardiz-
es cell functions, cellular secretions included – and thus
also the extracellular matrix and those cells physiological-
ly dependent on the altered cells or simply nearby – up to
the maximum degree that may be caused by gradual
senescence. As the transition to the altered physiological
conditions determined by cell senescence, and the reverse
passage – by the activation of telomerase [51-55] –
towards a condition in which all cellular functions are
intact, is a bidirectional on/off transformation, this type
of cell alteration has been defined as “on/off senescence”
[10].
Absence of a relationship between longevity and initial
telomere length or telomerase activity. In the comparison
between species, an easy prediction, however falsified by
the evidence, is a direct relation between longevity and
initial telomere length (i.e. that in the germ cell) and,
similarly, between longevity and the degree of telomerase
activity. However, many facts disprove these predictions:
a) hamsters and mice have longer telomeres than our
species but age more precociously [56];
b) among rodents, there is no relationship between
telomerase activity and maximum lifespan [57];
c) mice show a baseline activity of telomerase in
most somatic cells [58], but have limited longevity;
d) two Mus strains, the first with a telomere length of
20 kb and the other of only 10 kb, show equal life spans
and the same timing patterns of cell senescence [19];
e) analogously, cloned animals derived from somatic
cells, which have shortened telomeres, show the same
senescence timing of donor animals [19];
Fig. 3. The telomere shortens with each replication and the heterochromatin hood slides over the subtelomere, repressing an increasing por-
tion of subtelomeric DNA, which probably means the repression of the hypothetical “r” sequences. This allows for alterations in gene expres-
sion in different and distant parts of the DNA molecule (modified and redrawn from Fig. 4 of [10]).
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f) in telomerase knockout (mTR–/–) mice, which
have genetically inactivated telomerase, only after four
[59] to six [60] generations, when telomeres are very
shortened, it is possible to see, at least in artificially pro-
tected laboratory conditions, that fertility and viability are
jeopardized. However, in organs with high cell turnover,
the alterations are found in early generations [59, 61], so,
fitness would likely be reduced under natural conditions.
These phenomena, which are apparently inexplicable
if you want to assign an exclusive role in longevity deter-
mination to telomere length, on the contrary are com-
pletely explicable if it is assumed that in the germ cell, in a
phase – defined as the “reset” phase – before the first cell
replication, the heterochromatin hood is formed with a
size proportional to telomere length. In this reset phase,
regarding the longevity, the absolute “telomere length is
irrelevant” [19], provided of course that telomere length is
not less than a critical size [19]. Afterwards, in proportion
to the number of duplications and so to the progressive
shortening of the telomere (if it is not elongated by telom-
erase), there is progressive sliding of the heterochromatin
hood, and thus proportional repression of the subtelom-
ere, which causes the manifestations of gradual senes-
cence and increases the probability of cell senescence, i.e.
on/off senescence plus replicative senescence.
For this model, it is necessary that: (i) the hete-
rochromatin hood must have a fixed length in all the cells
of the organism; (ii) the telomere elongation by telom-
erase up to the initial length must somehow have the hood
length as a limiting factor. It is certainly necessary to
study the mechanisms underlying these phenomena,
which must be phylogenetically very old.
In fact, as described above, in yeast, with an evolu-
tionary history that diverged from that of our species at
least at the beginning of Cambrian era, i.e. about 600 mil-
lion years ago [62]: (i) in the normal stocks, at each dupli-
cation, each cell restores telomere length on the basis of
the heterochromatin hood size, which is then kept fixed
despite the succession of generations; (ii) in the daughter
cells of tlc1∆ mutants, where telomerase is inactive, the
telomere shortens with each division, but the hood
remains at a fixed length and represses the subtelomere by
sliding on it.
All this indicates that, as regards longevity, the criti-
cal element is not the absolute initial length of the telom-
ere, but the progressive inhibition of subtelomeric DNA
caused by telomere shortening [10, 19]. The aforemen-
tioned phenomena (a-f) are illustrated and interpreted in
Fig. 5 for phenomena a, b, and c; in Fig. 6 for d and e; and
in Fig. 7 for f.
Consequences of gradual senescence and cell senes-
cence. The effects of gradual senescence and cell senes-
cence (on/off senescence + replicative senescence) on
the organism as a whole, considered under natural condi-
tions, are the likely roots of all aging manifestations, as
already proposed and explained elsewhere [17-19].
In short, we have an “atrophic syndrome” of all tissues
and organs, which is the consequence of: (i) an age-related
Fig. 4. Telomeres oscillate between the “capped” and “uncapped” conditions. The probability of uncapped telomeres increases in proportion
to subtelomere repression of hypothetical repetitive sequences (“r”) that regulate the degree of adhesion between the heterochromatin hood
and the telomere. In the uncapped state, the non-protected telomere is a free end of the DNA molecule and is susceptible to end-to-end join-
ing that blocks cell replication [48].
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Fig. 5. In case 1, there are shorter subtelomeres and longer telomeres than in case 2. After a certain number of duplications, by assuming that
telomeres are equally shortened at each generation in the two cases, in case 1 the shorter subtelomeres are more impaired by the sliding of the
heterochromatin hood, which should lead to earlier aging. If we assume for case 1 also a greater mean telomerase activity, which contrasts
telomere shortening, this may be insufficient to compensate for greater subtelomeric repression. This model is an easy explanation for phe-
nomena (a), (b), and (c).
Fig. 6. Case 1: Mus strain with 20 kb telomeres; case 2: Mus strain with 20 kb telomeres (or case 1: donor animals; case 2: cloned animals). In
case 1, cells have longer telomeres and heterochromatin hoods than in case 2 cells, but the longevity is the same: the progressive gradual senes-
cence and the increasing probability of cell senescence activation are not a function of telomere absolute initial length but of progressive sub-
telomere repression, caused by relative telomere shortening. This model explains phenomena (d) and (e).
after n
duplications
after n
duplications
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increase in the percentage of cells with altered functions, to
varying degrees, due to gradual senescence and on/off
senescence; (ii) an age-related decline in the speed and
completeness of cell turnover due to the progressive
increase in the percentage of stem and somatic cells in
replicative senescence; (iii) perennial cells, i.e. cells with-
out turnover (e.g. almost all neurons), are compromised
and die by the phenomena (i)-(ii) in satellite cells (glial
cells), which show turnover and are essential for their func-
tionality, causing problems that are considered distinct dis-
eases (Alzheimer’s disease, Parkinson’s disease, age-related
macular degeneration, etc. [63]); (iv) the consequent (to
phenomena (i)-(iii)) reduction in functional cells in a tissue
or organ, partially replaced by nonfunctional cells, and the
related decline in tissue or organ functionality [17, 18].
The related alterations reduce fitness, i.e. the ability
to survive under natural conditions. In contrast, under
protected conditions, even a remarkable fitness reduction
can be compatible with survival, but, at older ages, the
progressive worsening of the above-mentioned tissue/
organ alterations becomes lethal even under artificial
conditions of greatest protection, which are non-existent
in the wild [18, 64].
Distinction between aging and diseases whose fre-
quency and severity increases with age. It is essential to
make a clear distinction between the physiological
process of aging and several diseases that are virtually
absent under natural conditions [18, 64] and often
increase in frequency and severity over the years (e.g.
hypertension, type 2 diabetes, vascular diseases, various
types of cancer, etc. [18]).
These diseases, as a rule, are due to changes in the
ecological niche (eating habits, lifestyles, pollutants in
the environment, etc.) to which the species is not adapt-
ed and which are therefore harmful [18]. Some of these
alterations, here defined as “risk factors”, are countered,
at least in part, by medications or other measures (“pro-
tective factors”).
The distinction between the aforesaid diseases and
the aging process is that these problems are, at least par-
tially, preventable or curable by the appropriate restora-
tion of the correct ecological niche or by opportune
drugs, while, on the contrary, aging, in principle – being
a physiological phenomenon – is not contrasted by pre-
ventive, protective, or curative actions. Lifestyles and
environmental conditions that are ideally perfect to pre-
serve health allow the achievement of physiological, i.e.
normal, aging but cannot block or reverse aging [18].
However, “risk factors” may cause an acceleration of the
aging process; “protective factors” may contrast this
acceleration and give the false impression of contrasting
aging while they only counteract pathologically altered
aging. A specific example is the gradual weakening of
endothelial function, which is a major cause of vascular
Fig. 7. In mice with telomerase genetically inactivated, the length of the heterochromatin hood, modeled on the telomere in the reset phase,
and that of the telomere in the first generation are equal to that of normal stocks. As telomerase is inactive, in each subsequent generation, the
initial length becomes shorter, up to fourth to sixth generation when the telomere shortens below viability limits. With each generation, the
subtelomere length is unvaried, because it is not influenced by telomerase. Within each generation, with each cell duplication, the telomere
shortens and the subtelomere is progressively inhibited by sliding of the heterochromatin hood. Therefore, as shown in the previous figure, this
genetic repression is a function of relative telomere shortening and not a function of the absolute initial telomere length [19]. This explains
phenomenon (f) (modified and redrawn from Fig. 6 of [10]).
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diseases and can be measured by counting endothelial
progenitor cells (EPCs) [65, 66]. EPC number, which is a
predictor of cardiovascular disease as reliable as the
Framingham score [67], decreases over the years and is
also reduced by risk factors. A healthy lifestyle or the
action of various drugs can restore the normal EPC num-
ber for the age but do not block the reduction related to
age [65]. These concepts are summarized in Fig. 8.
Surely, it is possible to propose alternative interpreta-
tions of the aging process that might be compatible with
the programmed aging paradigm (e.g. Olovnikov’s hypo-
thetical “chronomeres” and “printomeres” as pivotal
parts of aging mechanisms [68, 69]), but we think that our
explanation is more consistent with evidence.
POSSIBLE INTERVENTIONS
The aim of this work is to search for feasible methods
to slacken, block, or reverse the normal mechanisms of
aging. It must be stressed that many common diseases
caused by alterations in the ecological niche, or by other
factors: (i) are not part of the normal process of aging,
even if their frequency and seriousness may often be age-
related; (ii) can be prevented or treated with appropriate
measures; and (iii) are not part of this goal.
For our species, in individuals who are in the best
physical condition and free from any disease that could
endanger their fitness, there is a progressive age-related
fitness decline, which starts from about 30 years: “No one
would consider a man in his thirties senile, yet, according
to athletic records and life tables, senescent is rampant
during this decade” [70]. In fact, this decline may some-
how be quantified by observing the world speed records
for each age group (Fig. 9).
Methods to reverse aging should transform the curve
of fitness decline into a straight horizontal line, i.e. a fit-
ness or mortality rate that is constant at any age. The
search for these methods will be based exclusively on the
interpretation of the aging mechanisms outlined above.
Method 1: telomerase activation. The evaluation of
aging mechanisms and the experiments carried out so far
Fig. 8. A scheme of the aging process. Evolutionary causes are not discussed in this work.
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suggest immediately that the simplest and best way to
arrest aging is telomerase activation to bring telomere
length to the initial one, defined by the size of the hete-
rochromatin hood.
Well-known and already mentioned experiments on
cultured cells have shown since 1998 that telomerase acti-
vation can completely reverse the features of cell senes-
cence, namely to totally rejuvenate cells with the markers
of cell senescence [51-55].
At the tissue level, in vitro-aged fibroblasts with
“substantial alterations in gene expression” were treated
with telomerase and then “assessed by incorporation into
reconstituted human skin”, which showed no biological
difference with skin obtained from young fibroblasts
[71].
At the organismal level, in aged mice with artificial-
ly blocked telomerase, telomerase reactivation shows a
marked reversal of degenerative manifestations, even for
the nervous system [72]. Moreover, in one- and two-year-
old normal mice, telomerase expression, induced by
adeno-associated viruses carrying the mouse telomerase
reverse transcriptase, delays aging and increases longevity
(increase in median lifespan of 24 and 13%, respectively)
without increasing cancer risk [73].
The use of telomerase reactivation to control aging is,
however, wrongly hampered by a formidable non-technical
difficulty originating in the assumptions of the old para-
digm, which is still the dominant thesis although its validity
as a scientific theory is strongly opposed by evidence and
theoretical arguments [12]. In fact, according to the old
paradigm, genetically determined and regulated mecha-
nisms that progressively impair fitness simply cannot exist.
Therefore, the subtelomere–telomere– telomerase system,
concisely described in the previous section and supported
by strong evidence, for the old paradigm, cannot have aging
as an evolutionary motivation but must absolutely have
another reason that justifies its existence. The only motiva-
tion that has so far been proposed to justify these mecha-
nisms is the old one that interprets them as a general defense
against cancer [74, 75]. Replicative senescence would con-
stitute an effective obstacle to cancer proliferation. Thus,
aging would be just a side effect of this defense, in a sort of
terrible evolutionary trade-off between the problems of
aging and the need to defend the organism from cancer
[76], in excellent compatibility with the ideas maintained by
some old traditional evolutionary hypotheses about the evo-
lutionary causes of aging (antagonistic pleiotropy theory
[70, 77]; disposable soma theory [78, 79]).
Fig. 9. Quantification of age-related fitness decline based on data from modern populations, namely on speed records for various distances in
individuals younger than 35 (world records; source: http://en.wikipedia.org/wiki/World_records_in_athletics), and in other age groups
(source: http://www.world-masters-athletics.org/records_output/rec_list_outdoor_m.php). From the beginning of adulthood to an age of
about 30-35 years, we observe the best performance, i.e. the greatest fitness, and this is the period with the lowest mortality observed under
natural conditions [7].
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However, several strong arguments are against the
aforesaid explanation, as in part already explained else-
where [18, 64]: a) there are animal species without any
age-related fitness decline (“animals with negligible
senescence” [4]) and old individuals of such species (e.g.
rainbow trout and lobster) have under natural conditions
the same telomerase activity shown by young individuals
[80, 81], but there is no age-related increased vulnerabil-
ity to cancer, as their constant mortality at any age shows;
b) gradual senescence and on/off senescence cause a pro-
gressive weakening of immune system efficiency [19], and
this increases vulnerability to cancer and so cancer inci-
dence [82]; c) shortened telomeres cause DNA instabili-
ty, and this increases the probabilities of cancer onset [83-
85]; d) in eukaryotic unicellular species such as yeast,
replicative senescence and apoptosis, not caused by
shortened telomeres but by ERC accumulation, are well-
documented [27, 33, 86], but cannot be a defense against
cancer, as it is impossible in unicellular species; e) grad-
ual senescence, i.e. the existence of critical regulatory
sequences in subtelomeric DNA that are gradually
repressed because of telomere shortening, is an implausi-
ble defense against neoplastic cell proliferation; f) in
mice, the selective elimination of senescent cells
(p16Ink4a+ cells) contrasts several age-dependent changes,
delays the progression of malignant diseases, and increas-
es lifespan [87], and this is against the possibility that
senescent cells are a defense against cancer; g) in humans
studied in the wild: (i) the survivors at ages 60 and 70 were
approximately 30 and 20%, respectively; (ii) cancer cases
were not reported and only in a few older individuals (>70
years) there was the possibility that death was caused by
cancer. In the same population, the age-related increase
in mortality, i.e. aging, was evident starting from the thir-
ties. The hypothesis that the mechanisms underlying this
increment of mortality could be a defense against a rare
disease which shows its deadly effects at later ages is
clearly illogical [64]; h) telomerase activation, which is a
common feature in cancer, as it is subsequent to and does
not precede cancer onset, must be considered a cancer
aggravating phenomenon and not a cause of it [19].
It must be stressed that with the rejection of the
aforesaid explanation for cell aging mechanisms as a
defense against cancer, the old paradigm loses a valuable
last trench and becomes even more untenable. This
explains historically and psychologically, but does not jus-
tify scientifically, the tenacious defense of this explana-
tion, which is a heavy unjustified brake against the use of
telomerase to counter aging.
However, in overcoming this difficulty, the main way
to slow aging is clearly telomerase activation and the sub-
sequent restoration of the telomere to its initial length
[88].
One possibility is the use of drugs that are capable of
such action. Certain substances, called astragalosides,
have shown some action in reactivating telomerase [89,
90], but are remarkably expensive and their effect is lim-
ited [88].
However, the technique that appears to be more effec-
tive and more feasible in a short time is telomerase activa-
tion by telomerase reverse transcriptase (TRT) introduced
into the organism using an adenovirus as a vector, as in an
experiment carried out with significant positive results in
mice and already mentioned in this work [73].
This must necessarily be accomplished through sev-
eral phases:
1) new experiments on animals to study: (i) the best
techniques to introduce TRT into the organism with the
highest standards of efficiency and security; (ii) further
details on the results, also as a function of the age of the
individual when the technique is applied;
2) first experiments on elderly human subjects suffer-
ing from diseases that are seriously debilitating and are
part of aging process, such as Alzheimer’s disease,
Parkinson’s disease, age-related macular degeneration,
etc. (excluding precocious cases likely due to genetic
defects or to harmful lifestyles), and possibly in individu-
als not in a condition to reproduce, to avoid possible
transmission of an altered genome;
3) experiments on subjects with less disabling dis-
eases, or even on individuals with reproductive capacity if
the possibility of genome alteration has been excluded;
4) experiments for the treatment of subjects suffering
from other diseases that may be considered a conse-
quence of aging process acceleration;
5) experiments for the treatment of healthy elderly
individuals, i.e. simply to rejuvenate them.
Method 1 would allow for the rejuvenation of the
organism with the limit that any irreversible changes (for
example, macro-structural alterations, reduction in stem
cell number) would not be correctable. Therefore, it
should be applied early enough (e.g. before the age of 40)
and repeated relatively frequently (e.g. 10 years). Clearly
these are reasonable assumptions that require due confir-
mation.
Method 2: subtelomere modification. It is possible to
envisage a different method based on genetic modifica-
tions to subtelomeres such as to increase the age at which
fitness decline begins to manifest (i.e. about 30 years in
our species [70]). For example, if it were possible to
increase this age from 30 to 60 and if, in conjunction with
this method, we apply method 1 at the age of 60 and then
every 30 years, we would lengthen the period of biological
youth without any treatment and minimize possible irre-
versible changes at the age when method 1 is applied.
Now, let us see the method that is proposed here.
Some abbreviations are necessary for a more concise
exposition:
– The telomere is composed of a monotonous repe-
tition of a motif (TTAGGG in vertebrates), which will be
indicated with “<m>”. So, if the motif is repeated n
times, the telomere will be described as “<m>n”;
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– That part of the subtelomere which is next to the
telomere and may be defined as the telomere–subtelom-
ere junction; it will be indicated with “<J>”;
– All the remaining part of the subtelomere will be
indicated with “<ST>”. According to these abbrevia-
tions, the terminal part of a chromosome will be indicat-
ed with: <ST><J><m>n;
– The abbreviation “<NS>” means a neutral
sequence, i.e. a sequence that has no negative or positive
action on the remaining part of the DNA molecule or on
any genetic or cellular function;
– The abbreviations “<c1>” and “<c2>” indicate
two sequences with distinct marker codes without any
identical sequence in the genome.
It is necessary to specify, inter alia, that:
– The study of the <J> sequence is preliminary to
the development of the method. It is essential that the
<J> sequence is, or is delimited, such that there is no
identical sequence in the genome;
– Likewise, the definition of one or more neutral
sequences (<NS>) will be preliminary.
The objective of method 2 is to achieve the insertion
of one or more sequences <NS> between <ST> and
<J>, namely to get the following structure of the
terminal part of the chromosome: <ST><J><m>n →
<ST><NS>y<J><m>n, where y is an integer arbitrarily
chosen for convenience.
To achieve this result, by using a technique such as
CRISPR-CAS9, the following procedure might be feasi-
ble:
1) substitution of <J> with the sequence
<c2><NS><c1>:
<ST><J><m>n → <ST><c2><NS><c1><m>n;
2) substitution of <c1> with <J>:
→ <ST><c2><NS><J><m>n;
3) substitution of <c2> with the sequence
<c1><NS>:
→ <ST><c1><NS>2<J><m>n;
4) substitution of <c1> with the sequence
<c2><NS>:
→ <ST><c2><NS>3<J><m>n;
5) repetition of the steps 3 and 4 until <NS> is
repeated y times:
→ <ST><c1 or c2><NS>y<J><m>n;
6) removal of <c1 or c2>:
→ <ST><NS>y<J><m>n, which is the required
result.
We should note that each sequence that marks where
an operation must be performed (e.g. <J> in (1)) is always
destroyed by the action, so that it cannot be executed
more than once.
This change would have effect both on the individual
on which it is performed, and for individuals of the fol-
lowing generations if it has been accomplished in germ
cells.
From a theoretical point of view, it would be useless
to lengthen the subtelomere beyond the maximum length
for which the subtelomere can be inhibited by telomere
shortening before the telomere reaches a critical mini-
mum length and cell senescence is obligatorily triggered.
Fig. 10. a) Method 1 (M1) is applied several times, the first at age 50 and then every 20 years; b) the subtelomere has been lengthened by
method 2, and then method 1 is applied several times, the first at age 80 and then every 50 years; c) the subtelomere has been lengthened by
method 2 and the telomere by method 3, and then method 1 is applied several times, the first at age 110 and then every 80 years. The gray lines
show fitness decline when method 1 is not applied.
a
b
c
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This method has an important advantage. As it takes
place on the subtelomere and not on the telomere, exper-
iments would be easily feasible in a S. cerevisiae animal
model that “ages” because of subtelomere inhibition not
caused by telomere shortening but by progressive ERC
accumulation. As the optimal result, in a strain of S.
cerevisiae modified by this method, the maternal lineage
cells should stop their replications after several duplica-
tions greater than the 25-35 limit found by Jazwinski
[27].
After acquiring a good mastery of the techniques to
be employed, the method should be applied on a multi-
cellular animal model with short longevity (e.g. mice) and
afterwards on animals whose longevity and physiology are
closer to our species (e.g. pigs).
As for method 1, with the reservations expressed in
the Introduction (in particular for the following step (c)),
the subsequent steps may be conceived with the accom-
panying application (possibly repeated) of method 1: a)
application on human subjects who are unable to procre-
ate and suffer from serious diseases such as Alzheimer’s
disease, Parkinson’s disease, age-related macular degen-
eration, etc.; the possible success of this approach, partic-
ularly for diseases like Alzheimer’s and Parkinson’s,
would also allow a decisive discrimination between their
interpretation as coherent and critical parts of the aging
mechanisms [63] and other interpretations related to bio-
chemical events and functional disorders of the same dis-
eases (e.g.: [91-94]); b) application on elderly subjects
who are unable to procreate but are healthy; c) modifica-
tion of the germ cells of healthy individuals.
Method 3: telomere elongation without the use of
telomerase. By operating after the reset phase, telomerase
can lengthen the telomere to the maximum length
allowed by the heterochromatin hood. By using an alter-
native method on germ cells, it is possible to envisage
telomere elongation up to the desired length. In both
cases, since the heterochromatin hood is modeled in the
reset phase according to telomere length, this does not
affect longevity. However, if the subtelomere has been
modified by method 2, this would allow more telomere
shortening before the telomere length reaches a critical
level. In short, the combined use of method 2 and method
3 would lead to a longer period before reaching the stage
at which fitness begins to decline and there is a need to
resort to method 1 for restoring fitness.
So, if the goal is to achieve telomere elongation by
adding y repeats of the sequence <m>f (where y and f are
integers arbitrarily chosen according to convenience),
namely: <ST><J><m>n → <ST><J><m>n+yf, the fol-
lowing procedure might be feasible:
1) substitution of <J> with the sequence
<c1><m>f<c2>:
<ST><J><m>n → <ST><c1><m>f<c2><m>n;
2) substitution of <c1> with <J>:
→ <ST><J><m>f<c2><m>n;
3) substitution of <c2> with the sequence
<m>f<c1>:
→ <ST><J><m>2f<c1><m>n;
4) substitution of <c1> with the sequence
<m>f<c2>:
→ <ST><J><m>3f<c2><m>n;
5) repetition of the steps 3 and 4 until the sequence
<m>f is repeated y times:
→ <ST><J><m>yf<c1 or c2><m>n;
6) removal of <c1 or c2>:
→ <ST><J><m>n+yf, which is the required result.
Figure 10 illustrates by way of example the three
methods outlined here.
Clearly, what is proposed in the last section might be
considered exceedingly speculative. However, the pur-
pose of this work is precisely to speculate what would be
possible to perform to slacken or block the aging process,
starting from the necessary condition of the truthfulness
of the new paradigm – not discussed here – and of what
is known about the subtelomere–telomere–telomerase
system as a result of a considerable amount of evidence.
In no way will this be accepted by those who reject a
priori the new paradigm, but the same are requested to
consider what is proposed here by accepting the new par-
adigm only as a working hypothesis, i.e. the revolutionary
idea that aging is a physiological phenomenon deter-
mined and regulated by genes and therefore in principle
modifiable.
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